Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: Phase III Study

NCT01359956 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.

NCT NCT01359956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01359956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: Phase III Study
Lead sponsor
National Cancer Institute, Naples
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2002
Completion date
February 28, 2011
Enrollment
269 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma, recurrent melanoma